Загрузка...
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). In recent years, several investigational agents mainly targeting angiogenesis failed in late-phase clinical development due to either toxicity or lack of benefit. Recently, data of the RE...
Сохранить в:
| Опубликовано в: : | J Hepatocell Carcinoma |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5036543/ https://ncbi.nlm.nih.gov/pubmed/27703962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S112537 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|